Carfilzomib Earns Strong Positive Vote From FDA Advisory Committee
The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has voted 11 to zero with one abstention in favor of carfilzomib's bid to be approved as a new treatment for multiple myeloma.
Specifically, the majority of the committee voted that the risk-benefit assessment for carfilzomib (Kyprolis) is favorable for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy.
Today's vote by the FDA committee went much better for carfilzomib than had been expected. A recent survey of major Wall Street investors, for example, showed a significant majority expecting a negative vote by the FDA panel (see related Beacon news).
In addition, an FDA briefing document for today's meeting that was released earlier this week voiced strongly worded concerns about carfilzomib's safety. Publication of the FDA report caused the stock of Onyx Pharmaceuticals (NASDAQ:ONXX), the company developing carfilzomib, to drop more than 4 percent.
During today's meeting, however, the FDA staff presentation regarding carfilzomib's efficacy and safety was considerably less critical of carfilzomib. In its discussion of potentially life-threatening side effects of the drug, for example, the FDA presentation noted that they occurred "with a low frequency" during relevant clinical trials.
In contrast, the presentations by Onyx employees and myeloma opinion leaders presenting on carfilzomib's behalf laid out a strong case for both the efficacy and safety of the drug.
As a result, the momentum was in carfilzomib's favor for most of today's meeting. (See the Beacon's live coverage of today's meeting for details of all the presentations and question-and-answer sessions during the carfilzomib review.)
Onyx completed an application to the FDA last September to have carfilzomib as a new myeloma treatment (see related Beacon news).
The FDA will consider the advisory committee’s vote as well as comments made during today’s meeting when deciding whether to approve carfilzomib's new drug application.
Although the FDA is not legally bound to follow its advisory committees’ recommendations regarding new drug applications, it usually does.
The FDA is required to make a decision about carfilzomib’s application by July 27. It also has the option, however, of extending this deadline if it feels it needs additional time to complete its review.
For more information about the FDA’s ongoing review of the carfilzomib application, see the latest Beacon news about carfilzomib.
Related Articles:
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- Once-Weekly High-Dose Kyprolis Yields Deeper Responses And Longer Remissions Than Twice-Weekly Kyprolis (ASCO & EHA 2018)
- Eyelid-Related Complications Of Velcade Therapy: New Insights And Recommendations
- Common Measures Of Heart And Blood Vessel Health May Predict Risk Of Heart-Related Side Effects During Treatment With Kyprolis
- ASCO 2018 Update – Expert Perspectives On The Key Multiple Myeloma-Related Oral Presentations
YAY!!! .....on to FDA approval next!!
Good news for MM patients!!
Carfilzomib has worked almost miraculously for me....knock on wood... and many others in the newly diagnosed trials, so I say a big YES!!!! This will help all afflicted my MM.
Terry L.
Yes suzie rose. good news for the 75% of patients who can tolerate çarfilsomib.
The rest of us can only hope that the FDA will recommend
that onyx use the available tools in the personalized medicine
Arsenal to getting the dose individualized so we can benefit from
Carfilzomib as well.
I agree GAry!!
We need every tool (drug) in the box, to manage this disease. For every person it helps it is such a wonderful thing, even if some are helped more than others. No one drug is a panacea. We do have to be informed and make good choices. But thank the lord, we have choices!!
..praying for even MORE choices...
Great news! Now I will work on spelling it... carfilozeb...carfilozomib carfilzomib.
Krypolis...sort of sounds like "cripple us". I'll stick with carfilzomib.
Since Velcade didn't do much for me, is it true that carfilzomib has a lower chance of working for me?
Either way, I'm happy for the MM community.
hehehehe Stan!
you 2 funneee! "cripple us"...lol lol
Carfilzomib could work since it works at a different site...know the safety profile...and try it and see. IF the FDA approves it...we not HOME yet!!..this was just advisory cmte
Hi guys. Happy for your excitement, but difficult to share it.
I tend to say the the real problem for our desease is not the front line therapy but the therapy for relapsed/refractory patients. So ok we have undoubtedly got a new tool (many thanks to the researchers for their unvaluable effort), but no big change (am I wrong ?) for relapse/refractoriness (22% of overall response, ?together with Dex).
Hi Tiziano,
I agree that 22% is far from stellar. Unfortunately, that is the up-to-date progress for MM...I too wish it was far better. Nevertheless, it is good for all MM patients to have more choices,no?
Even with the 22% some relapsed/refractory patients will be able to delay disease progression, perhaps until another agent becomes available. One thing I have noticed about some of the clinical trials in the RR patient population is that some have had 5 prior therapies. That offers hope as despite prior failure those patients were still able to manage their disease and continue on to a different therapy.
The choices with myeloma are just not easy. I wish they were.
Also remember that when Velcade was approved it only had a 27% overall response in the RR environment. The 22% response rate for Carfilzomib includes patients that stopped responding to Velcade.
Later tests using Velcade combined with Revlimid and Dex in newely diagonsed patients showed an almost 100% response rate.
The use of Carfilzomb is being sought for RR patients that have aleady gone through 2 other lines of treatment.
To me this is great and exciting news. Now on to getting Pomalidomide approved!
Ron
Thank you for underlyning the meaning of that 22%. I agreed that it gives us more chance. Maybe I was expecting more as I had been hearing about Carfilzomib for a few years already. I remain not excited but I agree this is a hard achievement against myeloma and that today is time for celebrating.
Progress toward fundraising goal
for all of 2020:
15%
For more information, see the Beacon's
"2020 Fundraising: Goals And Updates" page